Ashvattha Therapeutics to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences.*Conference Details:*

*BIO CEO & Investor Conference*

*Format:* Corporate Presentation
*Date: *Tuesday, February 27, 2024
*Time: *11:45 – Noon ET
*Location:* The New York Marriott Marquis

Ashvattha’s Co-Founder and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please reach out via the BIO One-on-One Partnering system.

*Evercore ISI 2024 Emerging Biotech Conference*

*Format:* Fireside Chat
*Date:* Thursday, February 29, 2024
*Time:* 11:20 – 11:50 am ET
*Location:* Virtual

Members of Ashvattha’s management team will provide an update on the company’s multiple Phase 2 clinical trials and upcoming data readouts.

*About Ashvattha Therapeutics *
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For more information, visit: www.avttx.com

*Media Contact*
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
628-234-3889